XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Segment revenues:

 

 

 

 

 

 

 

 

Software

 

$

26,340

 

 

$

23,812

 

Drug discovery

 

 

5,787

 

 

 

2,362

 

Total segment revenues

 

$

32,127

 

 

$

26,174

 

Segment gross profit:

 

 

 

 

 

 

 

 

Software

 

$

20,434

 

 

$

19,811

 

Drug discovery

 

 

(4,270

)

 

 

(4,186

)

Total segment gross profit

 

 

16,164

 

 

 

15,625

 

Unallocated:

 

 

 

 

 

 

 

 

Research and development

 

 

(21,448

)

 

 

(13,700

)

Sales and marketing

 

 

(5,239

)

 

 

(4,789

)

General and administrative

 

 

(13,389

)

 

 

(8,936

)

Loss on equity investments

 

 

(1,781

)

 

 

 

Change in fair value

 

 

24,824

 

 

 

(3,079

)

Interest income

 

 

420

 

 

 

699

 

Income tax expense

 

 

(74

)

 

 

(91

)

Consolidated net loss

 

$

(523

)

 

$

(14,271

)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the three months ended March 31, 2021 and 2020:

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

United States

 

$

16,905

 

 

$

13,486

 

Europe

 

 

10,545

 

 

 

8,281

 

Japan

 

 

1,535

 

 

 

1,970

 

Rest of World

 

 

3,142

 

 

 

2,437

 

 

 

$

32,127

 

 

$

26,174